In France, corticosteroid therapy has been widely used for DMD since 2005 and has changed the practice of pediatric rehabilitation teams. Here, the authors describe their 10-year clinical experience of treating DMD patients with corticosteroids (CS) according to international guidelines i.e. prednisone 0.75mg/kg/day started from the plateau of motor function. Increased appetite, irritability, cushingoid facies are common but well tolerated by children. Dose adjustments are discussed on a case by case basis depending on accelerated weight gain, sluggish growth in stature and behavioral disorders.